Delivery Order SPE2DB20D3304-SPE2DB25FW8X5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,579.01 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, awarded on August 14, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $11,629.29 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price contract was competitively awarded without set-aside designation and carries an ultimate completion date of September 8, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which is valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,347.84 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,614.04 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, awarded on September 10, 2025, without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,033.29 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $2,566.94 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,812.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and carries an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,425.07 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This competitively awarded, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside procurement. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D3304Indefinite Delivery Contract
- SPE2DB20D3304-SPE2DB25FW8X5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,492.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by September 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same city. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Ondansetron, an antiemetic medication commonly used in medical settings, represents one component of the extensive pharmaceutical portfolio the company furnishes through this strategic contract vehicle to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare system customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 9/8/25 |